Multiple Myeloma
Original Research
RVD With Weekly Bortezomib Has a Favorable Toxicity and Effectiveness Profile in a Large Cohort of US Veterans With Multiple Myeloma
Case Reports
The First Patient in the Veteran Affairs System to Receive Chimeric Antigen Receptors T-cell Therapy for Refractory Multiple Myeloma and the Role of Intravenous Immunoglobulin in the Prevention of Therapy-associated Infections
Case Reports
The First Female Patient in the Veteran Affairs System to Receive Chimeric Antigen Receptors (CAR) T-cell Therapy for Refractory Multiple Myeloma and the Role of CAR T-cell Therapy in Penta-refractory Disease
Conference Coverage
One Patient Changed This Oncologist’s View of Hope. Here’s How.
“How we think about hope directly influences patient care,” according to a professor of clinical medicine at Weill Cornell Medicine in New York...
News
Obesity and Cancer: Untangling a Complex Web
Is gaining weight later in life better or worse for cancer risk than being overweight or obese from a young age?
News
Urine Tests Could Be ‘Enormous Step’ in Diagnosing Cancer
Cancer biomarkers in urine are not nearly as widely studied as those in the blood, but a new wave of urine tests suggests research is gaining pace...
Conference Coverage
New mRNA Vaccines in Development for Cancer and Infections
Different forms and designations of mRNA vaccines are used, depending on the application and desired effect.
News
Can a Risk Score Predict Kidney Injury After Cisplatin?
Researchers have developed a risk algorithm to predict acute kidney injury after cisplatin administration and tested it using data from six US...
News
Do Patients Benefit from Cancer Trial Participation?
Researchers conduct a meta-analysis comprising 141 comparisons of an investigational drug and a control treatment, which include immunotherapies...
News
The Long, Controversial Search for a ‘Cancer Microbiome’
Research raised as many questions as answers about what we do and don’t know about microbiota and cancer.